Fradet Laurent, Charters Emma, Gao Kan, Froggatt Catriona, Palme Carsten, Riffat Faruque, Nguyen Kevin, Wu Raymond, Milross Chris, Clark Jonathan R
Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Division of Otolaryngology, Department of Surgery, Faculty of Medicine, Université de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada.
ANZ J Surg. 2022 Mar;92(3):511-517. doi: 10.1111/ans.17463. Epub 2022 Jan 11.
Post-operative radiotherapy (PORT) volumes and dose to target structures likely influence swallowing function and quality of life following transoral robotic surgery (TORS). The aim of this study is to analyse disease control and swallowing outcomes in patients undergoing TORS for oropharyngeal squamous cell carcinoma (OPSCC) to determine the impact of omitting the primary site from the PORT treatment volume.
Prospectively collected data from patients that underwent TORS between March 2013 and April 2021 were reviewed. Patients were categorized into three groups: (1) no PORT, (2) PORT to the neck alone or (3) PORT to the primary site and neck. Survival curves were generated according to the Kaplan-Meier method and swallowing was assessed using the Functional Oral Intake Scale, Public Status Scale Head and Neck, MD Anderson Dysphagia Inventory and feeding tube/gastrostomy dependence.
A total of 121 patients underwent TORS, of which 103 met inclusion criteria with a median follow up of 2.6 years. No patients developed local recurrence. The 3-year regional control rates were 90%, 100% and 100% for groups 1, 2 and 3, respectively. Disease-specific survival was 97% over the study period. Patients that received PORT to both the primary site and the neck (group 3) had worse swallowing outcomes at 12 months.
Following TORS for OPSCC, avoiding PORT to the primary site, in appropriately selected patients, appears to be oncologically safe and is associated with superior swallowing outcomes.
术后放疗(PORT)的靶区体积和剂量可能会影响经口机器人手术(TORS)后的吞咽功能和生活质量。本研究的目的是分析接受TORS治疗口咽鳞状细胞癌(OPSCC)患者的疾病控制情况和吞咽结果,以确定在PORT治疗体积中省略原发部位的影响。
回顾性分析2013年3月至2021年4月期间接受TORS治疗患者的前瞻性收集数据。患者分为三组:(1)未接受PORT,(2)仅对颈部进行PORT,或(3)对原发部位和颈部进行PORT。根据Kaplan-Meier方法生成生存曲线,并使用功能性口服摄入量量表、头颈公共状态量表、MD安德森吞咽障碍量表和喂养管/胃造口术依赖情况评估吞咽功能。
共有121例患者接受了TORS治疗,其中103例符合纳入标准,中位随访时间为2.6年。无患者出现局部复发。第1、2和3组的3年区域控制率分别为90%、100%和100%。在研究期间,疾病特异性生存率为97%。接受原发部位和颈部PORT治疗的患者(第3组)在12个月时吞咽结果较差。
对于OPSCC患者,在TORS治疗后,对于适当选择的患者,避免对原发部位进行PORT似乎在肿瘤学上是安全的,并且与更好的吞咽结果相关。